Discounted Cash Flow Rating
Buy
Return on Equity Rating
Strong Sell
Debt to Equity Rating
Buy
Price to Earnings Rating
Buy
Analyst Rating
Neutral
Wall Street Data Solutions Rating
Neutral
B
Aligos Therapeutics, Inc. Common Stock (ALGS)
Biological Products, (no Disgnostic Substances)
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA
Current Price
---.--
% Change Today
0.00%
Change Amt. Today
0.00
Active Status
Active
Listing Date
10/16/2020
Market Cap
39,787,684
Shares Outstanding
71,840,000
Weighted SO
74,931,848
Total Employees
N/A
Upcoming Earnings
08/01/2024
Similar Tickers
Beta
2.1830
Last Div
0.0000
Range
0.348-1.2
Chg
0.0379
Avg Vol
461325
Mkt Cap
39787684
Exch
NASDAQ
Country
US
Phone
800 466 6059
DCF Diff
0.3604
DCF
0.1426
Div Yield
0.0000
P/S
4.9941
EV Multiple
-0.0489
P/FV
1.2054
Div Yield %
0.0000
P/E
-1.0700
PEG
-0.0383
Payout
0.0000
Current Ratio
4.2255
Quick Ratio
4.2255
Cash Ratio
1.9160
DSO
0.0000
DIO
0.0000
Op Cycle
0.0000
DPO
908.3704
CCC
-908.3704
Gross Margin
0.6561
Op Margin
-11.7394
Pretax Margin
-9.4795
Net Margin
-9.5061
Eff Tax Rate
-0.0022
ROA
-0.6960
ROE
-1.1059
ROCE
-1.0971
NI/EBT
1.0028
EBT/EBIT
0.8075
EBIT/Rev
-11.7394
Debt Ratio
0.0904
D/E
0.1463
LT Debt/Cap
0.0879
Total Debt/Cap
0.1276
Int Coverage
6.7798
CF/Debt
-8.6645
Equity Multi
1.6185
Rec Turnover
0.0000
Pay Turnover
0.4018
Inv Turnover
0.0000
FA Turnover
0.9253
Asset Turnover
0.0732
OCF/Share
-0.5448
FCF/Share
-0.5454
Cash/Share
0.6047
OCF/Sales
-10.6983
FCF/OCF
1.0011
CF Coverage
-8.6645
ST Coverage
-25.4048
CapEx Coverage
-897.1895
Div&CapEx Cov
-897.1895
P/BV
1.2054
P/B
1.2054
P/S
4.9941
P/E
-1.0700
P/FCF
-0.4663
P/OCF
-0.9508
P/CF
-0.9508
PEG
-0.0383
P/S
4.9941
EV Multiple
-0.0489
P/FV
1.2054
DPS
0.0000
Latest Headlines (EST)
Revenue Product Segmentation
2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2024 | |
---|---|---|---|---|---|---|---|
Revenue | X | X | X | ▲ XXXXXX | ▲ XXXXXXX | ▼ 2.68M | ▼ 986.00K |
Cost Of Revenue | X | X | X | X | ▲ XXXXXX | ▼ 775.00K | ▼ 674.00K |
Gross Profit | X | X | X | ▲ XXXXXX | ▲ XXXXXXX | ▼ 1.91M | ▼ 312.00K |
Gross Profit Ratio | X.XXXXXXXXXX | X.XXXXXXXXXX | X.XXXXXXXXXX | ▲ X.XXXXXXXXXX | ▼ X.XXXXXXXXXX | ▼ 0.71 | ▼ 0.32 |
Research And Development Expenses | XXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▲ 22.26M | ▼ 16.37M |
General And Administrative Expenses | XXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▼ XXXXXXX | ▼ 6.42M | ▲ 6.67M |
Selling And Marketing Expenses | X | X | X | X | X | ▼ -775.00K | ▲ 0.00 |
Selling General And Administrative Expenses | XXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▼ XXXXXXX | ▼ 5.65M | ▲ 6.67M |
Other Expenses | -XXXXXXX | ▲ XXXXX | ▲ XXXXXXX | ▼ X | X | ▼ -460.00K | ▼ -13.37M |
Operating Expenses | -XXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▲ 27.90M | ▼ 23.03M |
Cost And Expenses | XXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▲ 28.68M | ▼ 23.03M |
Interest Income | X | ▲ XXXXXX | ▼ XXXXX | ▲ XXXXXX | ▲ XXXXXX | ▲ 1.59M | ▼ 580.00K |
Interest Expense | X | X | ▼ -XXXXXXXX | ▲ XXXXXX | ▲ XXXXXX | ▼ -1.00M | ▼ -12.79M |
Depreciation And Amortization | XXXXXX | ▲ XXXXXX | ▲ XXXXXX | ▲ XXXXXXX | ▼ XXXXXX | ▼ 775.00K | ▼ 674.00K |
Ebitda | -XXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▲ -XXXXXXXX | ▼ -25.22M | ▲ -22.05M |
Ebitda Ratio | X.XXXXXXXXXX | X.XXXXXXXXXX | X.XXXXXXXXXX | ▼ -XX.XXXXXXXXXX | ▲ -X.XXXXXXXXXX | ▼ -9.41 | ▼ -22.36 |
Operating Income | -XXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▲ -XXXXXXXX | ▼ -26.00M | ▲ -22.05M |
Operating Income Ratio | X.XXXXXXXXX | X.XXXXXXXXX | X.XXXXXXXXX | ▼ -XXX.XXXXXXXXX | ▲ -X.XXXXXXXXX | ▼ -9.70 | ▼ -22.36 |
Total Other Income Expenses Net | -XXXXX | ▲ XXXXX | ▲ XXXXXXX | ▼ XXXXXX | ▲ XXXXXX | ▼ -1.93M | ▼ -12.79M |
Income Before Tax | -XXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▲ -XXXXXXXX | ▼ -27.92M | ▼ -34.84M |
Income Before Tax Ratio | X.XXXXXXXXXX | X.XXXXXXXXXX | X.XXXXXXXXXX | ▼ -XX.XXXXXXXXXX | ▲ -X.XXXXXXXXXX | ▼ -10.41 | ▼ -35.33 |
Income Tax Expense | -XXXXX | ▲ XXXXX | ▲ XXXXXX | ▼ -XXXXX | ▲ XXXXX | ▼ -30.00K | ▲ -24.00K |
Net Income | -XXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▼ -XXXXXXXX | ▲ -XXXXXXXX | ▼ -27.89M | ▼ -34.86M |
Net Income Ratio | X.XXXXXXXXXX | X.XXXXXXXXXX | X.XXXXXXXXXX | ▼ -XX.XXXXXXXXXX | ▲ -X.XXXXXXXXXX | ▼ -10.40 | ▼ -35.36 |
Eps | -X.XX | ▼ -X.XX | ▼ -X.XX | ▲ -X.XX | ▲ -X.XX | ▲ -0.37 | ▲ -0.22 |
Eps Diluted | -X.XX | ▼ -X.XX | ▼ -X.XX | ▲ -X.XX | ▲ -X.XX | ▲ -0.37 | ▲ -0.22 |
Weighted Average Shs Out | XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ 75.10M | ▲ 156.15M |
Weighted Average Shs Out Dil | XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▲ 75.10M | ▲ 156.15M |
Link | View | View | View | View | View | View | View |
Final Link | View | View | View | View | View | View | View |
2019 | 2021 | 2022 | 2023 | 2024 | 2024 | 1970 | |
---|---|---|---|---|---|---|---|
Cash And Cash Equivalents | XXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXXX | ▼ 24.37M | ▼ |
Short Term Investments | XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXX | ▲ XXXXXXXX | ▼ X | ▲ 88.59M | ▼ |
Cash And Short Term Investments | XXXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▲ XXXXXXXXX | ▼ 112.96M | ▼ |
Net Receivables | X | X | X | X | X | 0.00 | |
Inventory | X | X | X | X | X | 0.00 | |
Other Current Assets | XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXX | ▼ XXXXXXX | ▼ 5.11M | ▼ |
Total Current Assets | XXXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▲ XXXXXXXXX | ▼ 118.06M | ▼ |
Property Plant Equipment Net | XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXX | ▼ 9.21M | ▼ |
Goodwill | X | X | X | X | X | 0.00 | |
Intangible Assets | X | X | X | X | X | 0.00 | |
Goodwill And Intangible Assets | X | X | X | X | X | 0.00 | |
Long Term Investments | XXXXXXXX | ▼ X | ▲ XXXXXXXX | ▼ X | X | 0.00 | |
Tax Assets | X | X | X | ▲ XXXXXXX | ▼ XXXXXXX | ▼ 0.00 | |
Other Non Current Assets | XXXXXX | ▲ XXXXXX | ▲ XXXXXX | ▼ -XXXXXXX | ▲ XXXXXX | ▲ 625.00K | ▼ |
Total Non Current Assets | XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▼ 9.84M | ▼ |
Other Assets | X | X | X | X | ▲ X | ▼ 0.00 | |
Total Assets | XXXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▲ XXXXXXXXX | ▼ 127.90M | ▼ |
Account Payables | XXXXXXX | ▼ XXXXXXX | ▼ XXXXXXX | ▲ XXXXXXX | ▼ XXXXXXX | ▲ 2.84M | ▼ |
Short Term Debt | XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▲ XXXXXXX | ▲ 3.27M | ▼ |
Tax Payables | X | X | X | X | X | 0.00 | |
Deferred Revenue | XXXXXXX | ▲ XXXXXXX | ▼ XXXXXXX | ▲ XXXXXXX | ▼ XXXXXXX | ▼ 721.00K | ▼ |
Other Current Liabilities | XXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ 12.04M | ▼ |
Total Current Liabilities | XXXXXXXX | ▲ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▼ 18.88M | ▼ |
Long Term Debt | XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXX | ▼ XXXXXXX | ▼ 7.21M | ▼ |
Deferred Revenue Non Current | X | ▲ XXXXXXX | ▼ -XXXXXXX | ▲ XXXXXX | ▼ X | 0.00 | |
Deferred Tax Liabilities Non Current | X | ▼ -XXXXXXXX | ▲ -XXXXXXX | ▼ -XXXXXXX | ▲ XXXXXXX | ▼ 0.00 | |
Other Non Current Liabilities | XXXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXX | ▲ XXXXXXXX | ▲ 42.02M | ▼ |
Total Non Current Liabilities | XXXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXX | ▲ XXXXXXXX | ▲ 49.23M | ▼ |
Other Liabilities | X | X | X | X | X | 0.00 | |
Capital Lease Obligations | XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXX | ▼ 7.21M | ▼ |
Total Liabilities | XXXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▲ 68.11M | ▼ |
Preferred Stock | X | ▲ XXXXXXXXX | ▼ X | X | X | 0.00 | |
Common Stock | X | ▲ XXXX | XXXX | XXXX | ▲ XXXX | 7.00K | ▼ |
Retained Earnings | -XXXXXXXX | ▼ -XXXXXXXXX | ▼ -XXXXXXXXX | ▼ -XXXXXXXXX | ▼ -XXXXXXXXX | ▼ -521.66M | ▼ |
Accumulated Other Comprehensive Income Loss | -XXXXXX | ▼ -XXXXXX | ▲ XXXXXX | ▼ XXXXXX | ▲ XXXXXX | ▼ 476.00K | ▼ |
Other Total Stockholders Equity | XXXXXXX | ▲ XXXXXXXXX | ▲ XXXXXXXXX | ▲ XXXXXXXXX | ▲ XXXXXXXXX | ▲ 580.97M | ▼ |
Total Stockholders Equity | -XXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXX | ▼ 59.80M | ▼ |
Total Equity | -XXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXX | ▼ 59.80M | ▼ |
Total Liabilities And Stockholders Equity | XXXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▲ XXXXXXXXX | ▼ 127.90M | ▼ |
Minority Interest | X | X | X | X | X | 0.00 | |
Total Liabilities And Total Equity | XXXXXXXXX | ▲ XXXXXXXXX | ▼ XXXXXXXXX | ▼ XXXXXXXXX | ▲ XXXXXXXXX | ▼ 127.90M | ▼ |
Total Investments | XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ X | ▲ 88.59M | ▼ |
Total Debt | XXXXXXXX | ▼ XXXXXXXX | ▲ XXXXXXXX | ▼ XXXXXXXX | ▼ XXXXXXXX | ▼ 10.49M | ▼ |
Net Debt | -XXXXXXXX | ▼ -XXXXXXXXX | ▲ -XXXXXXXXX | ▲ -XXXXXXXX | ▼ -XXXXXXXXX | ▲ -13.88M | ▼ |